Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
70771-1626-08 70771-1626 Fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 14, 2021 In Use
70710-1688-08 70710-1688 fulvestrant FULVESTRANT 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Dec. 14, 2021 In Use
75834-0132-05 75834-0132 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0132-14 75834-0132 Temozolomide Temozolomide 5.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0142-05 75834-0142 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0142-14 75834-0142 Temozolomide Temozolomide 20.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0143-05 75834-0143 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0143-14 75834-0143 Temozolomide Temozolomide 100.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0144-05 75834-0144 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0144-14 75834-0144 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0145-05 75834-0145 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
75834-0145-14 75834-0145 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Dec. 7, 2021 In Use
80425-0072-01 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-02 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-03 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-04 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
80425-0072-05 80425-0072 Ondansetron 4mg, Ondansetron HCL Ondansetron HCL 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 31, 2007 In Use
81565-0202-02 81565-0202 DEXAMETHASONE SODIUM PHOSPHATE Dexamethasone Sodium Phosphate 4.0 mg/mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Dec. 15, 2021 In Use
42291-0321-01 42291-0321 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral July 23, 2013 In Use
42291-0505-01 42291-0505 Methotrexate Methotrexate 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Oct. 5, 2020 In Use
42388-0013-14 42388-0013 Cabozantinib COMETRIQ 20.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR Oral Nov. 29, 2012 In Use
43975-0256-05 43975-0256 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral July 13, 2016 In Use
43975-0256-14 43975-0256 Temozolomide Temozolomide 180.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral July 13, 2016 In Use
44087-3535-01 44087-3535 Avelumab Bavencio 20.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-L1 Intravenous March 23, 2017 In Use
44087-4000-00 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-04 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-05 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-06 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-07 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-08 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
44087-4000-09 44087-4000 Cladribine Mavenclad 10.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral April 1, 2019 In Use
50742-0404-01 50742-0404 Topotecan Topotecan 4.0 mg/4mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 7, 2016 In Use
50742-0423-10 50742-0423 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0428-02 50742-0428 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 7, 2017 April 30, 2021 In Use
50742-0420-01 50742-0420 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0427-05 50742-0427 Vinorelbine Vinorelbine 50.0 mg/5mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0445-05 50742-0445 Carboplatin Carboplatin 50.0 mg/5mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 6, 2017 Feb. 12, 2018 In Use
50742-0446-15 50742-0446 Carboplatin Carboplatin 150.0 mg/15mL Chemotherapy Alkylating Agent Platinum Compound Intravenous May 6, 2017 Feb. 12, 2018 In Use
50742-0481-20 50742-0481 FLUOROURACIL FLUOROURACIL 50.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0482-50 50742-0482 fluorouracil FLUOROURACIL 2.5 g/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0483-99 50742-0483 fluorouracil FLUOROURACIL 5.0 g/100mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 21, 2019 In Use
50742-0512-20 50742-0512 Clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Sept. 27, 2018 In Use
50742-0525-07 50742-0525 arsenic trioxide ARSENIC TRIOXIDE 2.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous Jan. 27, 2021 In Use
54879-0021-01 54879-0021 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
54879-0022-01 54879-0022 CYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral May 8, 2018 In Use
54879-0027-11 54879-0027 Arsenic Trioxide Arsenic Trioxide 1.0 mg/mL Chemotherapy Miscellaneous Agent PML/RARa Intravenous May 29, 2019 In Use
72187-0401-01 72187-0401 Tagraxofusp Elzonris 1000.0 ug/mL Immunotherapy Fusion Protein IL3/ CD123 Intravenous Jan. 18, 2019 In Use
73380-4700-01 73380-4700 MOXETUMOMAB PASUDOTOX LUMOXITI 1.0 mg/mL Immunotherapy Drug Antibody Conjugate CD22 Intravenous May 15, 2020 In Use
50242-0245-01 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous June 29, 2020 In Use
50242-0245-86 50242-0245 Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Phesgo 30000.0 U/15mL, 1200.0 mg/15mL, 600.0 mg/15mL Immunotherapy Monoclonal Antibody HER2 Subcutaneous May 3, 2021 In Use

Found 10,000 results in 2 millisecondsExport these results